Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus indicus
- Development stage
- Unknown
- Lead developer
- Novones
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Bacillus indicus* is a Gram-positive, spore-forming, alkaliphilic bacterium notable for its ability to produce a variety of yellow and orange carotenoids. In the clinical and nutraceutical space, the strain HU36 is frequently utilized as a probiotic, often as a component of multi-strain formulations like MegaSporeBiotic. It is characterized by its high stability under gastric conditions and its capacity to colonize the gastrointestinal tract, where it exerts antioxidant and anti-inflammatory effects. Clinical studies have explored its efficacy in reducing post-prandial endotoxemia, lowering triglyceride levels, and improving symptoms of metabolic syndrome and psoriasis. Beyond its use as a probiotic, specific strains of *B. indicus* are researched for their production of L-asparaginase for potential antileukemic therapy and for their molluscicidal activity against *Oncomelania hupensis* snails.
- Brand names
- MegaSporeBiotic
- Other names
- Bacillus indicus HU36Bacillus indicus HU16Bacillus indicus F19Bacillus indicus TMC-6
Beyond the preview
Go deeper on bacillus indicus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus indicus.